Showing 2391-2400 of 5771 results for "".
- Sangamo Announces Completion of TxCell Acquisitionhttps://modernod.com/news/sangamo-announces-completion-of-txcell-acquisition/2476169/Sangamo Therapeutics announced the completion of the acquisition of TxCell, which is now a subsidiary of Sangamo and has been delisted from the French stock market. “The acquisition of
- Ocular Therapeutix Announces FDA Approval of Dextenza for the Treatment of Ocular Pain Following Ophthalmic Surgeryhttps://modernod.com/news/ocular-therapeutix-announces-fda-approval-of-dextenza-for-the-treatment-of-ocular-pain-following-ophthalmic-surgery/2476171/Ocular Therapeutix announced that the FDA has approved Dextenza (dexamethasone ophthalmic insert) 0.4mg for intracanalicular use for the treatment of ocular pain following ophthalmic surgery. Dextenza is the first FDA-approved intracanalicular insert delivering dexamethasone to treat post-
- Orasis Announces Appointments of Richard L. Lindstrom, Eric D. Donnenfeld, and John Berdahl to its Scientific Advisory Boardhttps://modernod.com/news/orasis-announces-appointments-of-richard-l-lindstrom-eric-d-donnenfeld-and-john-berdahl-to-its-scientific-advisory-board/2479644/Orasis Pharmaceuticals announced the appointment of Richard L. Lindstrom, MD, Eric D. Donnenfeld, MD, and John Berdahl, MD, to its scientific advisory board. Dr. Lindstrom, Dr. Donnenfeld, and Dr. Berdahl have joined existing scientific advisory board members Sheri Rowen, MD, and Michael Korenfel
- 4D Molecular Therapeutics Announces FDA Orphan Drug Designation Granted to 4D-110 for the Treatment of Choroideremiahttps://modernod.com/news/4d-molecular-therapeutics-announces-fda-orphan-drug-designation-granted-to-4d-110-for-the-treatment-of-choroideremia/2479659/Gene therapy company 4D Molecular Therapeutics (4DMT) announced that the FDA has granted orphan drug designation to 4D-110 for the treatment of choroideremia. Choroideremia (CHM) is an X-linked monogenic recessive disease (caused by mutation of the REP-1 gene) starting with reduced night v
- Eyegate Pharma Announces Positive Results in Punctate Epitheliopathy Studyhttps://modernod.com/news/eyegate-pharma-announces-positive-results-in-punctate-epitheliopathy-study/2479668/EyeGate Pharmaceuticals announced topline data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage patients with punctate epitheliopathies (PE) due to pathologies such as dry eye. “A product t
- Eyegate Pharma Announces Positive Results in Second PRK Studyhttps://modernod.com/news/eyegate-pharma-announces-positive-results-in-second-prk-study/2479671/EyeGate Pharmaceuticals announced topline data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of care. “T
- Eyenovia Announces FDA Acceptance of MicroStat IND Application for Mydriasishttps://modernod.com/news/eyenovia-announces-fda-acceptance-of-microstat-ind-application-for-mydriasis/2479672/Eyenovia announced that the FDA has accepted the company’s investigational new drug (IND) application to initiate phase 3 trials of MicroStat for diagnostic mydriasis.
- Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet AMDhttps://modernod.com/news/ophthotech-announces-results-from-phase-2a-safety-trial-of-zimura-in-combination-with-lucentis-in-wet-amd/2479673/Ophthotech announced the results from its phase 2a safety trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combinat
- Johnson & Johnson Vision Announce $26.35 Million Collaboration for Prevention and Treatment of Myopiahttps://modernod.com/news/johnson-johnson-vision-announce-26-35-million-collaboration-for-prevention-and-treatment-of-myopia/2479677/The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI), and Johnson & Johnson Vision announced a $26.35 million research collaboration to tackle myopia. By 2050, half of the world’s population are projected to be myopic, with one billion expected to have high my
- EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for Dexycu by CMShttps://modernod.com/news/eyepoint-pharmaceuticals-announces-assignment-of-permanent-j-code-for-dexycu-by-the-center-for-medicare-and-medicaid-services-cms/2479679/EyePoint Pharmaceuticals announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a specific and permanent reimbursement J-code through the Healthcare Common Procedure Coding System (HCPCS) for Dexycu (dexamethasone intraocular suspension) 9%. Dexycu is the first and only